Editorial contact

What we can help with

We respond to two kinds of message.

Corrections. If a citation on this site is mis-attributed, a number is misreported, a publication has been retracted, or a more recent peer-reviewed paper supersedes a finding we summarise, please tell us. Include the page, the specific sentence, and the corrected source. Corrections are reviewed against the underlying publication and applied promptly.

Citation suggestions. New peer-reviewed retatrutide literature, additional TRIUMPH program readouts, and supplementary trial analyses are welcome. Include the DOI or PubMed/PMC identifier and a one-sentence note on what the paper adds.

For either type of message, please use the form below or write to the editorial address indicated. We do not guarantee a personal reply to every message but we do read everything.

What we cannot help with

We cannot provide medical advice. We cannot answer questions about whether retatrutide is appropriate for a particular person, condition, or set of circumstances. We cannot recommend a dose, a titration schedule, or a duration of use. We cannot refer to a clinician, a clinical trial enrolment site, or a supplier.

For medical questions, please consult a licensed clinician in your jurisdiction. For information about enrolling in a retatrutide clinical trial, search the ClinicalTrials.gov registry directly using the relevant NCT identifier (for example, NCT05929066 for TRIUMPH-1 or NCT05882045 for TRIUMPH-3) and follow the contact details listed for the study sites.

This site does not sell, supply, or distribute any product and is not affiliated with any vendor or manufacturer.

Contact form

Please use the form to send a message. Include the page URL where relevant and a DOI or PubMed/PMC link for any cited source. All submissions are editorial; we do not share submitter information with third parties.

This site is an independent editorial digest of the published research literature — not a clinic, not a vendor, not a source of medical guidance.